RxDoctor Payments Data

Jose Torres Torres, MD

Internal Medicine · Guaynabo, PRNPI 1114923042

Payments from drug & device makers

$1,241in general payments, 2019–2025

Across 27 payments — averaging $45.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$452
  • Boehringer Ingelheim$375
  • E.r. Squibb & Sons, L.L.C.$244
  • Johnson & Johnson$82
  • Lilly USA, LLC$55
  • AbbVie$17
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$1,241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,241 in reported general payments places this provider in the 65th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$2,385
Medicare patients
12
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SynthroidLevothyroxine Sodium271$33,241
FarxigaDapagliflozin Propanediol22$24,307
JardianceEmpagliflozin17$23,438
XareltoRivaroxaban25$21,901
EliquisApixaban21$19,986
OzempicSemaglutide20$18,450
Pentoxifylline240$13,716
LantusInsulin Glargine,hum.Rec.Anlog66$13,430
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm67$11,975
TrulicityDulaglutide11$10,793
Candesartan Cilexetil72$9,486
Glipizide-MetforminGlipizide/Metformin Hcl90$6,486
Rosuvastatin Calcium412$5,878
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$5,802
Gabapentin406$5,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$17$33,241271 claims
Lilly USA, LLCHumulin 70-30, Trulicity, Humalog, Humulin N, Insulin Lispro$55$30,778136 claims
AstraZenecaFarxiga$452$24,30722 claims
Boehringer IngelheimJardiance$375$23,43817 claims
Johnson & JohnsonXarelto$82$21,90125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Guaynabo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →